About GLPG
GLPG is a company based in Mechelen (Belgium) founded in 1999. GLPG has raised $26.1 million across 21 funding rounds from investors including Gilead, Apax Partners and Crucell. The company has 704 employees as of December 31, 2024. GLPG has completed 3 acquisitions, including Abound Bio, CellPoint and Inpharmatica. GLPG offers products and services including Cell Therapy Platform and Small Molecules. GLPG operates in a competitive market with competitors including BeiGene, Biogen, Moderna, UCB and Incyte, among others.
- Headquarter Mechelen, Belgium
- Employees 704 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Galapagos Nv
-
Annual Revenue
$286.37 M (USD)14.99as on Dec 31, 2024
-
Net Profit
$76.96 M (USD)-65.01as on Dec 31, 2024
-
EBITDA
-$190.76 M (USD)-99.8as on Dec 31, 2024
-
Total Equity Funding
$26.1 M (USD)
in 21 rounds
-
Latest Funding Round
$410.58 M (USD), Post-IPO
Nov 01, 2019
-
Investors
Gilead
& 10 more
-
Employee Count
704
as on Dec 31, 2024
-
Investments & Acquisitions
Abound Bio
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GLPG
GLPG is a publicly listed company on the EURONEXT with ticker symbol GLPG in Netherlands, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GLPG
GLPG offers a comprehensive portfolio of products and services, including Cell Therapy Platform and Small Molecules.
Develops scalable cell therapies for oncology and hematological needs.
Assets targeting auto-immune diseases through clinical trials.
People of GLPG
Unlock access to complete
Unlock access to complete
Funding Insights of GLPG
GLPG has successfully raised a total of $26.1M across 21 strategic funding rounds. The most recent funding activity was a Post-IPO round of $410.58 million completed in November 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GLPG
GLPG has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Gilead, Apax Partners and Crucell.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Equity investments are focused on tech, services, and consumer sectors.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked |
Investor details for GLPG
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GLPG
GLPG has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Abound Bio, CellPoint and Inpharmatica.
Investment portfolio details for GLPG
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of discover, development, and manufacturing services for cancer and infectious disease
|
Locked | Locked | 2019 | Locked | |
|
CAR-T cell therapeutics are provided for hematological malignancies.
|
Locked | Locked | 2018 | Locked | |
|
Developer of predictive informatics based platform for drug discovery
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for GLPG
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - GLPG
Detailed financials for GLPG
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glpg Comparisons
Peer comparison for GLPG
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GLPG
GLPG operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Biogen, Moderna, UCB and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
Detailed competitors of GLPG
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glpg
Complete news archive for GLPG
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GLPG
GLPG was founded in 1999.
GLPG is headquartered in Mechelen, Belgium. It is registered at Mechelen, Antwerp, Belgium.
GLPG is a funded company, having raised a total of $26.1M across 21 funding rounds to date.
As of Dec 31, 2024, the latest employee count at GLPG is 704.
Annual revenue of GLPG is $286.37M as on Dec 31, 2024.
Founded in 1999 and headquartered in Mechelen, Belgium, small molecule drugs and antibody programs are discovered and developed by the company. Focus is placed on immunology, oncology, cystic fibrosis, inflammation, and other indications within the biotechnology sector. Operations involve advancing therapeutic candidates through research and clinical stages for various diseases.
GLPG's top competitors include Moderna, BeiGene and Strand Therapeutics.
GLPG offers Cell Therapy Platform and Small Molecules.
Yes, GLPG is publicly traded on EURONEXT under the ticker symbol GLPG.
GLPG has made 3 acquisitions, including Abound Bio, CellPoint, and Inpharmatica.
GLPG has 11 investors. Key investors include Gilead, Apax Partners, Crucell, Gimv, and European Union.
The ticker symbol of GLPG is GLPG on EURONEXT.